C61 Código facturable y específico Malignant neoplasm of prostate
ICD-10-CM C61 identifies “Malignant neoplasm of prostate” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 2: Neoplasms
Instrucciones del código
Excludes 11
malignant neoplasm of seminal vesicle (C63.7)
Use additional code3
- code, if applicable, to identify:
- hormone sensitivity status (Z19.1-Z19.2)
- rising PSA following treatment for malignant neoplasm of prostate (R97.21)
Instrucciones de niveles superiores
Capítulos 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C60-C63 · Malignant neoplasms of male genital organs (C60-C63)
Includes1
malignant neoplasm of skin of male genital organs
Referencias del índice oficial
Referencias del índice oficial (4)
Adenocarcinoma (1)
- Adenocarcinoma › duct › unspecified site › maleÍndice de enfermedades
Carcinoma(malignant) (1)
- Carcinoma(malignant) › endometrioid › unspecified site › maleÍndice de enfermedades
Cystadenocarcinoma (1)
- Cystadenocarcinoma › endometrioid › unspecified site › maleÍndice de enfermedades
Neoplasm, neoplastic (1)
- Neoplasm, neoplastic › prostate(gland)Neoplasias
Referencias desde otros códigos (2)
Excludes 2 · malignant neoplasm of prostate (C61)
Code first · malignant neoplasm of prostate (C61)
Historial
Historial del código
Último cambio registrado · FY2023
ModificadoSin cambios
FY2023
Vigente desde
- Cambios en instrucciones
Malignant neoplasm of prostate
Código de diagnóstico facturable
CDC/NCHS · FY2023Todas las ediciones (19)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2016 | 2015-10-01 | Primera aparición |
| FY2017 | 2016-10-01 | Cambios en instrucciones |
| FY2018 | 2017-10-01 | Sin cambios tabulares |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Cambios en instrucciones |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Sin cambios tabulares |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Sin cambios tabulares |
Correspondencias históricas ICD-9 · 2018
Solo correspondencia histórica; no sustituye códigos automáticamente.
- 185
Esta entrada es un código completo en la edición seleccionada. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.